Published in J Transplant on March 15, 2011
The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. J Transplant (2014) 0.86
Erzhi Pill® Repairs Experimental Liver Injury via TSC/mTOR Signaling Pathway Inhibiting Excessive Apoptosis. Evid Based Complement Alternat Med (2017) 0.75
Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology (2010) 3.54
Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl (2003) 1.61
A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation (2004) 1.30
Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl (2008) 1.18
Sirolimus in liver transplantation. Transplant Proc (2003) 1.13
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation (2007) 1.11
Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl (2001) 1.03
A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl (2007) 1.02
Sirolimus-induced pneumonitis following liver transplantation. Liver Transpl (2007) 1.01
Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl (2001) 0.93
A retrospective review of sirolimus (Rapamune) therapy in orthotopic liver transplant recipients diagnosed with chronic rejection. Liver Transpl (2003) 0.90
Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl (2003) 0.90
Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl Int (2007) 0.86
Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients. Transpl Int (2009) 0.85
A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation. Aliment Pharmacol Ther (2006) 0.84
Sirolimus conversion for renal preservation in liver transplantation: not so fast. Liver Transpl (2008) 0.82
Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl (2001) 0.82
Low incidence of cytomegalovirus disease in liver transplant recipients receiving sirolimus primary immunosuppression with 3-day corticosteroid taper. Transpl Infect Dis (2003) 0.81
Sirolimus and mycophenolate mofetil after liver transplantation. Transpl Int (2003) 0.80
Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation. Hepatobiliary Pancreat Dis Int (2007) 0.79
Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. Aliment Pharmacol Ther (2004) 0.78
Sirolimus: efficacy in liver transplant patients with nephrotoxicity and renal insufficiency. Transplant Proc (2007) 0.78
Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma. Expert Opin Pharmacother (2007) 0.78
Effect of sirolimus on infection incidence in liver transplant recipients. Liver Transpl (2004) 0.77
Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med (2002) 6.64
Choledochoduodenostomy is a safe alternative to Roux-en-Y choledochojejunostomy for biliary reconstruction in liver transplantation. World J Surg (2009) 3.47
Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg (2005) 2.64
Posttraumatic pneumatocele. J Am Coll Surg (2005) 2.02
Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD. Liver Transpl (2004) 1.66
A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One (2010) 1.62
Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl (2003) 1.61
Retracted Signaling through hepatocellular A2B adenosine receptors dampens ischemia and reperfusion injury of the liver. Proc Natl Acad Sci U S A (2013) 1.59
Comprehensive cost comparison of adult-adult right hepatic lobe living-donor liver transplantation with cadaveric transplantation. Transplantation (2003) 1.46
Vasopressin in the cardiac surgery intensive care unit. Am J Crit Care (2002) 1.44
Herpes simplex in a liver transplant recipient. Liver Transpl (2006) 1.39
Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients. Liver Transpl (2003) 1.31
Fulminant hepatic failure from primary hepatic lymphoma: successful treatment with orthotopic liver transplantation and chemotherapy. Transplantation (2005) 1.23
Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl (2008) 1.19
Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl (2008) 1.18
ICAM-1 and VCAM-1 mediate endotoxemic myocardial dysfunction independent of neutrophil accumulation. Am J Physiol Regul Integr Comp Physiol (2002) 1.13
A multicenter evaluation of safety of early extubation in liver transplant recipients. Liver Transpl (2007) 1.10
Outcomes of adult living donor liver transplantation: comparison of the Adult-to-adult Living Donor Liver Transplantation Cohort Study and the national experience. Liver Transpl (2011) 1.09
Adult-adult right hepatic lobe living donor liver transplantation for status 2a patients: too little, too late. Liver Transpl (2002) 1.08
Monocyte chemotactic protein-1 directly induces human vascular smooth muscle proliferation. Am J Physiol Heart Circ Physiol (2002) 1.08
Differential effects of plasma and red blood cell transfusions on acute lung injury and infection risk following liver transplantation. Liver Transpl (2011) 1.06
A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant (2005) 1.02
Donor complications following laparoscopic compared to hand-assisted living donor nephrectomy: an analysis of the literature. J Transplant (2010) 1.02
Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction. Am J Physiol Heart Circ Physiol (2002) 1.02
Atrial septal perforation from TIPS stent migration. J Vasc Interv Radiol (2004) 1.00
Incentives for organ donation: proposed standards for an internationally acceptable system. Am J Transplant (2011) 0.99
ALCAPA in an adult with preserved left ventricular function. J Card Surg (2003) 0.96
Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J Clin Endocrinol Metab (2012) 0.91
Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant (2004) 0.90
Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J Hepatol (2013) 0.90
Stem cells and myocardial repair. J Am Coll Surg (2002) 0.90
Equilibrative nucleoside transporter (ENT)-1-dependent elevation of extracellular adenosine protects the liver during ischemia and reperfusion. Hepatology (2013) 0.88
Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl (2003) 0.88
May-Thurner syndrome complicating left-sided renal transplant. Transplantation (2010) 0.88
Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl Int (2007) 0.86
Evaluation of the splanchnic circulation with indocyanine green pharmacokinetics in liver transplant patients. Liver Transpl (2002) 0.85
Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl (2003) 0.85
Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl (2008) 0.85
Reduced use of intensive care after liver transplantation: influence of early extubation. Liver Transpl (2002) 0.84
Adjustable gastric banding in a morbidly obese patient during liver transplantation. Obes Surg (2008) 0.82
Protective role for netrin-1 during diabetic nephropathy. J Mol Med (Berl) (2013) 0.82
Defining long-term outcomes with living donor liver transplantation in North America. Ann Surg (2015) 0.82
Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues. Liver Transpl (2013) 0.81
Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg (2006) 0.80
Transplant tourism and unregulated black-market trafficking of organs. Am J Transplant (2009) 0.80
Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients. Liver Transpl (2002) 0.80
Atherogenic effects of Chlamydia pneumoniae: refuting the innocent bystander hypothesis. J Thorac Cardiovasc Surg (2003) 0.79
Technical aspects for live-donor organ procurement for liver, kidney, pancreas, and intestine. Curr Opin Organ Transplant (2015) 0.79
Adult right lobe live donor liver transplantation without reconstruction of the middle hepatic vein: a single-center study of 109 cases. Transplantation (2008) 0.79
Hepaticoduodenostomy is an alternative to Roux-en-Y hepaticojejunostomy for biliary reconstruction in live donor liver transplantation. Transplantation (2009) 0.78
Reduced use of intensive care after liver transplantation: patient attributes that determine early transfer to surgical wards. Liver Transpl (2002) 0.78
Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma. Expert Opin Pharmacother (2007) 0.78
Use of a hanging-weight system for liver ischemia in mice. J Vis Exp (2012) 0.77
Pediatric liver transplantation. Curr Opin Pediatr (2004) 0.77
Living donor liver transplant for fibrolamellar hepatocellular carcinoma using a deceased donor graft to reconstruct inferior vena cava. Liver Transpl (2004) 0.76
The influence of OKT3 therapy on hepatocellular carcinoma recurrence following liver transplantation. Clin Transplant (2010) 0.76
Toll-like receptors and surgical disease. Surgery (2002) 0.76
Combined piggyback technique and cavoportal hemitransposition for liver transplant. Case Rep Med (2010) 0.76
Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity. Clin Transplant (2013) 0.75
Ischemic preconditioning: fact or fantasy? J Card Surg (2003) 0.75
Direct Anastomosis of the Donor Hepatic Artery to the Supraceliac Aorta without Extension Graft during Adult Liver Transplant in the Era of Extended Criteria Donors: Report of a Case. Case Rep Med (2010) 0.75
Hepatocellular carcinoma in a noncirrhotic patient with hereditary hemochromatosis. Am J Med Sci (2007) 0.75
Choledochoduodenostomy in pediatric liver transplantation. Pediatr Transplant (2011) 0.75
Hepatic hemodynamics and portal flow modulation: The A2ALL experience. Transplantation (2017) 0.75
595: PERIOPERATIVE 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE VERSUS FACTOR VIIA IN LIVER TRANSPLANTATION. Crit Care Med (2016) 0.75
Hydroxocobalamin for Vasoplegic Syndrome in Liver Transplantation: Restoration of Blood Pressure Without Vasospasm. A A Case Rep (2016) 0.75
Hepatic artery pseudoaneurysm - duodenal fistula after living donor liver transplant. Clin Transplant (2004) 0.75
Modified Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Hepatoblastoma in a Small Infant: How Far Can We Push the Envelope? Ann Surg (2017) 0.75
Bariatric surgery in liver transplant patients: weighing the evidence. Obes Surg (2008) 0.75